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Background: In the Republic in Congo, the national algorithm for the diagnosis of pulmonary tuberculosis (TB) relies on
Ziehl-Neelsen (ZN) sputum smear microscopy, chest X-ray radiography (CXR) and clinical symptoms. Microscopy positive
pulmonary TB (MPT+) is defined as symptoms of TB and a positive ZN smear. Microscopy negative pulmonary TB (MPT-)
is defined as symptoms of TB, a negative ZN smear but CXR changes consistent with TB. The present cross-sectional
study was designed to determine the prevalence of positive and negative MPT individuals among HIV positive and HIV
negative individuals presenting to an ambulatory TB treatment center (CTA) in Brazzaville.
Methods: All study participants underwent a physical examination, chest radiography and three ZN sputum smear
examinations and HIV testing. Viral load and CD4 counts were determined for HIV positive individuals.
Results: 775 individuals presented with symptoms of TB. 425 individuals accepted the voluntary HIV test. 133 (31.3%)
were HIV positive (HIV+) and 292 (68.7%) were HIV negative (HIV-). Of the 292 HIV- individuals 167 (57%) were classified
as positive MPT and 125 (43%) as negative MPT. Of the 133 HIV positive individuals 39 (29%) were classified as
MPT + and 94 (71%) as MPT-.
Conclusion: Our study shows that the prevalence of positive MPT individuals is lower among HIV positive individuals
compared to HIV negative individuals in agreement to reports from other countries. The data suggest that a substantial
number of HIV positive pulmonary TB cases are not detected by the national algorithm and highlight the need for new
diagnostic tests in this population.
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There are approximately 34 million people currently liv-
ing with HIV, one-third of these is estimated to also be
infected with tuberculosis (TB) [1-3]. Although antire-
trovirals (ARV) can reduce the risk of death in HIV in-
fected individuals, an untreated TB patient starting this* Correspondence: fntoumi@fcrm-congo.com
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reproduction in any medium, provided the ortherapy might be exposed to immune-reconstitution in-
flammatory syndrome (IRIS) which is associated with
increased morbidity and potential mortality [4].
In sub-Saharan Africa, TB is often the first manifest-
ation of HIV infection, and it is the leading cause of
death among HIV infected patients [5-7]. The countries
of the world with the highest HIV prevalence rates are
also those with high rates of TB [8], these countries in-
clude: Swaziland, Botswana, Lesotho, and South Africa
[1,9]. The highest number of TB/HIV co-infection has
been reported in southern Africa, where more than 60%
of TB patients are HIV positive [5,6,10]. The burden ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Republic of Congo. According to the World Health
Organization (WHO), in 2011, the incidence of TB in
Republic of Congo was 473 per 100,000 population
(including TB/HIV co-infections) and 31% of TB pa-
tients were HIV positive [11].
The diagnosis of HIV-associated TB is often challen-
ging and nucleic acid amplification tests, including the
GeneXpert MTB/RIF assay and urinary LAM assays are
known to improve the diagnosis of both smear-negative
and extrapulmonary TB in HIV positive individuals [12].
TB diagnosis worldwide currently heavily relies on
sputum smear microscopy to detect acid-fast bacilli
(AFB), as it is rapid, inexpensive, and highly specific for
identifying active pulmonary tuberculosis (PTB) [13,14].
This technique is known to identify the most cases with
excellent specificity, but has an approximate sensitivity of
35% to 70% [15-18]. Indeed, a particular challenge for cli-
nicians is the rising incidence of HIV related TB, often
associated with an increase in smear negative microscopy
cases [19-22] Unfortunately, the most sensitive techniques
available such as mycobacterial culture and nucleic acid
amplification techniques, are expensive, resource intensive
and thus not routinely available in many African countries
[23-27]. Current culture-based methods takes more
than two weeks [28] and there is a need for faster diag-
nosis of TB in HIV- and HIV + patients as well as de-
lays in diagnosis and treatment are associated with high
mortality risk [29-32].
In the Republic of Congo, the current national guide-
lines for TB diagnosis relies on sputum smear micros-
copy, X-ray radiography and clinical symptoms to
confirm TB cases (Figure 1). The present study is de-
signed as a diagnostic cross sectional study of HIV + and
HIV - patients suspected of having pulmonary TB. We
aimed to demonstrate the utility of the national diagno-
sis algorithm in confirming pulmonary TB in HIV + and
HIV -individuals. In addition we assessed virologic and
immunologic parameters in the HIV positive individuals.
More specifically, we seek to evaluate the need to imple-
ment new diagnostic tools to increase the detection rate
of TB in HIV+/sputum smear-negative cases.
Methods
Selection of patients
The study participants were recruited at the anti-
tuberculosis center (CAT) of Brazzaville during the
study period from February to June 2011. All consecutive
TB suspects regardless of HIV status were eligible for the
study. Informed consent was obtained from all study par-
ticipants or their guardians. Ethical authorization was
obtained from the Comité d’éthique Institutionnel de la
Recherche en Santé (CERSSA) (No. 00000067/DGRST/
CERSSA).Specimen collection
Demographic data (age, place of residence) and clinical
data were recorded for all participants during a medical
interview and a physical examination by a clinician.
Chest radiography and sputum collection was performed
according to the national diagnostic algorithm. Partici-
pants provided three sputum specimens over the course
of 2 days. The first specimen was collected when the pa-
tient attended the CAT for the first time. A container
was given to the participant for collecting an early
morning sample at home the next day, and a third was
collected again at the center when the patient brought
back the early morning specimen. The samples were
tested with the direct Ziehl-Neelsen light microscopy
method following standard instructions on proper spu-
tum submission. Sputum microscopy was performed at
the onsite laboratory, with density of acid fast bacilli
graded as 1, 2 or 3 + .
HIV testing
Blood samples were tested using two rapid tests, Deter-
mine HIV 1/2 test (Alere GmbH, Koln, Germany) and
ImmunoComb II HIV 1 & 2 BiSpot (Orgenics, Yavne,
Israel). In case of discordance between these two
tests, the enzyme-linked immunosorbent assay (ELISA,
Vironostika®HIV-1 Plus O Microelisa System, UK) was
performed by the reference lab which is the Laboratoire
National de Santé Publique.
CD4+/CD8+ cells counts
Approximately 5 ml of blood was collected in an EDTA
tube for counting T cells. The blood samples were proc-
essed immediately within 2 hours of collection, for de-
termination of the absolute counts of CD4+, CD8+ cells
by activated cell sorting (FACS) count (Partec GmbH,
Munster, Germany), following manufacturer’s instructions.
Quantification of plasma viral load
Quantification of plasma viral load of HIV-1 was done
using Biocentric™ kit, on a platform of Roche LightCycler ®
480 using the technique of real-time PCR. A volume of
10 ml obtained after RNA extraction from plasma was
used for analysis. The detection limit was 1,500 viral RNA
copies / ml (2.3 log copies / ml). The determination of viral
load was performed at the Laboratory of Molecular Biology
at the Faculty of Health Sciences /University Marien
Ngouabi, Brazzaville.
National diagnosis algorithm (Figure 1)
At the first consultation, all patients suspected of TB
were clinically assessed by a trained health professional.
The assessment includes screening for clinical signs and
symptoms such as current cough (if self-reported cough
was > 2 weeks), fever, night sweats and weight loss. Sputum
Ziehl Neelsen staining microscopy
Chest X Ray abnormalities 
consistent with active TB
Decision by a clinician to treat with the 
standard anti-TB treatment
Decision by a clinician to treat with a full course of 
anti-TB chemotherapy or no specific anti-TB 
treatment
Screen TB diagnosis, after 
15 days
Two positive sputum 
smear microscopy 
At least two negative 
sputum smear microscopy
Chest X Ray abnormalities 
consistent with active TB
TB suspected cases based on 
clinical symptoms 
Figure 1 National algorithm for the diagnosis of pulmonary TB.
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staining microscopy. A chest X-ray was performed and
HIV testing was offered to all individuals.
Case definitions
Pulmonary TB (PTB) positive microscopy: Patients with
at least 2 positive sputum samples were classified as
positive for pulmonary TB. These PTB positive patients
were given the standard anti-TB treatment according to
National guidelines.
Pulmonary TB negative microscopy: Patients with at
least 2 sputum samples negative for AFB and with symp-
toms of TB, a negative ZN smear but CXR changes con-
sistent with TB were classified as negative for pulmonary
TB. These PTB negative patients were treated with a
full course of anti-TB chemotherapy if 15 days later the
screening is positive.
Patients without pulmonary TB: Individuals with nega-
tive sputum samples for AFB and no X-ray changes sug-
gestive of TB.
Statistical analysis
The demographic, clinical and laboratory results were
entered into a database and analyzed using SPSS version
16 (SPSS Inc, Chicago, IL, USA). The mean and standard
deviation of the age, CD4 and CD8 T cells and viral load
were calculated using student’s t-test for comparison.Logistic regression was used to evaluate the effect of age,
gender and clinical parameters on HIV infection. Kruskal-
Wallis test was used to compare the proportion of HIV
infected patients with different levels of CD4+, CD8+ T
cells and viral load between AFB positive and negative mi-
croscopy. Differences were considered statistically signifi-
cant when the p value was ≤ 0.05.
Results
Characteristic of patients who consented to the HIV test
From February to June 2011, 775 patients attending the
consultation service at the TB center of Brazzaville
(CAT) were deemed suspected TB cases based on clin-
ical examination (Figure 2). Of these, 425 (54.8%) under-
went HIV testing at the time of TB diagnosis specimen
collection. Among these, 133 (31.3%) were HIV + and
292 were HIV-.
As presented on Table 1, the mean age of all partici-
pants was 34.9 years ±13.01 and most of the patients
were older than 25 years. Gender, signs of TB, axillary
temperature did not significantly differ according to HIV
status.
Of the 292 HIV- individuals, 167 (57%) were classified
as PTM positive and 125 (43%) as PTM negative. Of the
133 HIV + individuals 39 (29.3%) were classified as PTM
positive and 94 (70.7%) as PTM negative (Table 2 and
Figure 2). Thirty-six (92.3%) and thirty-five (37.2%) AFB
Number of TB suspected patients, who accepted 
to be tested for HIV = 425 (54.8%)
+ smear positive microscopy= 
39 (29.3%)
+ smear negative 
microscopy= 94 (70.7%)
CXR + = 35
(37.2%)
CXR - = 59
(62.8%)
Number of TB suspected patients HIV
negative = 292 (68.7%)
Number of TB suspected patients  
presenting clinical symptoms = 775
Number of suspected TB patients
HIV infected = 133 (31.3%)
CXR + = 36
(92.3%)
CXR - = 3
(7.7%)
+ smear positive microscopy
= 167(57%)
+ smear negative 
microscopy = 125 (43%)
CXR - = 4 
(3.2%)
CXR + = 
121 (96.8%)
CXR - =1 
(0.6%)
CXR + = 
166 (99.4%)
Figure 2 Sputum smear microscopy, HIV test and chest X-Ray results for the study participants. + means Patients with smear positive or
smear negative microscopy CXR means Chest X-ray.
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for X-ray (Figure 2) (<0.001).
CD4+/CD8+ T cells, viral load and sputum microscopy
examination in HIV patients
Concerning the 133 HIV patients, CD4+ T cells counts
have been reported according to the results of sputum
microscopy examination in Table 2. Overall mean
baseline CD4+ and CD8+ T cell count was 289.4 and
850.9 cells/ml respectively (Table 2). HIV + patients
with positive AFB had higher CD4+ counts (385.4 ± 278.1
cells/ml) when compared to those with a negative AFB
(239.6 ± 274.9 cells/ml) (p < 0.029). Patients with CD4 cell
counts below 350 cells/mm3 were significantly higher
among negative AFB patients (p < 0.007). The mean CD4/
CD8 ratio was significantly higher in positive smear pul-
monary tuberculosis than negative smear (0.59 versus 0.25,
P < 0.003).
The mean viral load was similar in AFB positive and
AFB negative groups and no significant difference be-
tween those with positive and negative AFB (Table 3)
was found.
Discussion
The burden of TB around the world remains alarming.
Microscopy examination of sputum samples is recom-
mended by the WHO as an essential step for patients
suspected of pulmonary TB. Unfortunately, smear mi-
croscopy has been reported to have low sensitivity [33].In particular, this technique has limited performance in
immune-compromised individuals [34]. A number of stud-
ies report that pulmonary TB diagnosis can be achieved
through the combination of clinical symptoms, CXR-
examinations and smear microscopy [35-37].
As in many countries with limited resources where TB
is endemic, the algorithm endorsed by the Congolese na-
tional TB control program emphasizes the use of these
modalities. In our study, we found that this algorithm
identifies less cases of PTB microscopy positive and PTB
microscopy negative in HIV + individuals compared to
HIV – individuals. It is important to keep in mind that
mycobacterial culture or nucleic acid amplification tests
are not available in our setting. This is a common limita-
tion encountered in African countries. The true preva-
lence of pulmonary tuberculosis in our setting is thus
not determined.
Our study showed that the rate of ZN smear positivity
is higher in HIV - than in HIV + individuals. Given the
well-known increased risk for pulmonary tuberculosis in
HIV + individuals the data suggest that a number of
HIV + individuals with pulmonary TB were not detected
by ZN based microscopy [3,6,9]. Moreover the lower
prevalence of CXR abnormalties in HIV + individuals
also suggests that this diagnostic modality may be less
sensitive in the HIV + population. Despite the limitation
in methodology the present data thus suggest that the
national diagnostic treatment algorithm may miss a sub-
stantial number of HIV + individuals with pulmonary
Table 1 Characteristics of patients (who accepted to do the HIV test) enrolled at the TB Center in Brazzaville
All HIV positive HIV negative Crude OR(95%CI) P-value
Number of patients 425(54.8) 133(31.3) 292 – –
Age (years)Mean ± SD 34.9 ± 1 38.37 ± 9 33.40 ± 1 – 0.000
Age group
14-24ans 98(23.7) 9(9.2) 89(90.8) Baseline
25-34ans 123(29.7) 33(26.8) 90(73.2) 3.6(1.64-8.01) 0.001
≥ 35ans 193(46.6) 84(43.5) 109(56.5) 7.6(3.63-16.00) <0.001
Missing 11
Gender
Female 177(42.3) 71(40.1) 106(59.9)
Male 241(57.7) 55(22.8) 186(77.2) 0.4 (0.29-0.67) <0.001
Missing 7
Signs of TB
No 99(23.9) 34(34.3) 65(65.7)
Yes 319(76.3) 92(28.8) 227(71.2) 0.7(0.48-1.25) 0.298
Missing 7
Cough
No 0(0) 0 0
Yes 418(100) 126(30.1) 292(69.9) – –
Missing 7
Pale skin
No 355(85.5) 101(28.5) 254(71.5)
Yes 60(14.5) 25(41.7) 35(58.3) 1.8(1.02-3.15) 0.041
Missing 10
Axillary temperature >37.5°C
No 37(8.9) 11(29.7) 26(70.3)
Yes 379(91.1) 114(30.1) 265(69.9) 1.02(0.48-2.13) 0.965
Missing 9
Asthenia
No 38(9.3) 8(20.5) 31(79.5)
Yes 378(90.6) 117(30.8) 261(69.2) 1.7(0.78-3.89) 0.180
Missing 8
Anorexia
No 80(19.1) 17(21.2) 63(78.8)
Yes 338(80.9) 109(32.2) 229(67.8) 1.7(0.98-3.16) 0.056
Missing 7
Weight loss
No 13(3.12) 2(15.4) 11(84.6)
Yes 404(96.9) 124(30.7) 280(69.3) 2.4(0.53-11.15) 0.251
Missing 8
Received TB treatment, after diagnosis
No 61(14.6) 54(88.5) 7(11.5)
Yes 357(85.4) 72(20.2) 285(79.8) 0.03(0.01-0.07) <0.001
Missing 7
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Table 2 CD4+ and CD8+ T cells counts in HIV Congolese patients with positive or negative sputum detected by
microscopy using Ziehl-Neelsen staining
All Positive microscopy Negative microscopy P-value*
Number of HIV-1 patients 133(31.3%) 39(29,3) 94(70.7) <0.001–
Immunological category (CDC)
CD4+ T-cell count (cells/mm3, mean ± SD) 289.4 ± 282.9 385.4 ± 278.1 239.6 ± 274.9 0.029
Absolute CD4+ T-cell counts 53(67.1) 12(44.4) 41(78.8)
<350/mm3 11(13.9) 7(26) 4(7.7) 0.007
350–500/mm3 15(19.0) 8(29.6) 8(13.5)
>500/mm3 54
Missing
CD8+ T-cell counts (cells/mm3, mean ± SD) 850.9 ± 547.4 647.3 ± 555.2 956.6 ± 517.5 0.016
Absolute CD8+ T-cell counts 18(22.7) 4(14.8) 14(26.9)
<400/mm3 16(20.3) 3(11.1) 13(25) 0.001
400–799/mm3 30(38) 8(29.6) 22(42.3)
800–1200/mm3 15(19) 12(44.5) 3(5.8)
>1200/mm3 54
Missing
CD4/CD8 ratio (mean ± SD) 0.34 ± 0.51 0.59 ± 0.5 0.25 ± 0.5 0.003
Missing 54
*: Chi-square Test.
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patients who are smear-negative in our study, may not
have TB. Against this background, we may speculate that
many patients could be over-treated for TB.
In our study, the mean CD4/CD8 ratio was lower than
1, this indicates an increase of PTB among HIV patients,
especially for negative smeargroup. Inability to properly
diagnose pulmonary TB in the HIV infected population
is hazardous to this immnuno-compromised population
due to the well-known increased severity of pulmonary
tuberculosis in TB-HIV co-infection. In addition there
is a risk of immune-reconstitution inflammatory syn-
drome (IRIS) in patients on antiretroviral therapy withTable 3 Viral load in HIV Congolese patients with sputum sm
Ziehl-Neelsen staining
All Smear posit
Number HIV-1 infected patients 133 39
Mean ± SD, log10 copies per ml 4.6 ± 1.6 4.7
Range (min.–max.),log10 copies / ml 2.60-7.5 2.6
Viral load group, copies per ml,%
<500 35(36.5) 1
501 – 10 000 22(22.9) 6
10 001 – 250 000 10(10.4)
>250 000 29(30.2) 8
Missing 37
**: Kruskal Wallis Test.undiagnosed and those with untreated TB [4], this is
unmasking TB IRIS. In other words, if TB remains un-
diagnosed in an HIV positive individual that starts anti-
retroviral therapy, there is a chance that the patient’s
immune system may begin to recover but then respond
to the TB infection with an overwhelming inflammatory
response of patient [38].
Many studies have confirmed the superior effective-
ness of culture methods when compared to smear mi-
croscopy [37,39,40]. To test TB diagnosis algorithms in
resource-limited areas, the standard of care (evaluation
through clinical symptoms, chest x-rays and smear mi-
croscopy) has been compared to confirmation of TBear positive or negative by microscopy stained using
ive microscopy Smear negative microscopy P-value
(29,3) 94(70.7) –
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(MGIT) technology which specifically detects and recovers
mycobacteria. In a study conducted in Sub-Saharan Africa
and South America, the standard of care method was less
sensitive in detecting TB than the culture method [39].
In Kenya, [35] a cross sectional study was conducted to
ascertain the performance of the 2007 World Health
Organization (WHO) algorithm to diagnose PTB in HIV
positive individuals. In this study, the use of culture
increased significantly the proportion of confirmed
TB cases. In 2010, WHO recommended the use of
XpertMTB/RIF for HIV positive patients in order to de-
tect Mycobacterium tuberculosis (Mtb) and rifampicin
resistance [41]. GeneXpertMTB/RIF were reported to
perform better than smear microscopy [42-44]. Recent
studies have shown that the urinary LAM test improves
the diagnosis of TB in HIV + individuals among those
who are severely immunocompromised, however this test
performance is high in the very sickest patients [45,46].
The limit of the National algorithm for the diagnosis
of TB infection is that no culture lab exists in the country.
Moreover, with regard to high risk of HIV people to
get TB infection, it would be very useful to test negative
sputum samples with the WHO endorsed GeneXpert
technology.
Conclusion
In countries were TB and HIV are endemic, accurate
and rapid diagnosis tools should be implemented. It is
crucial to have access low-cost tools that are adapted to
countries where resources are limited and to support
health care providers with adequate training. This study
showed that the current national treatment algorithm
may adequately detect smear positive pulmonary TB in
HIV- individuals.
In the present study, a consistent number of patients
with smear-negative microscopy and negative radiology
were found; therefore it is possible that many patients
with negative smear pulmonary TB did not have TB. In
order to avoid over-TB treatment, it appears urgent to
use locally specific diagnostic methods such as culture
or GeneXpert. However, our data also suggest that add-
itional diagnostic modalities are required to diagnose
TB in HIV + individuals, especially those with smear-
negative pulmonary tuberculosis.
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